Sun Pharma eyes future of specialty drugs with Organon buy
Bengaluru: India’s largest pharmaceutical company, Sun Pharmaceutical Industries Limited, has announced the largest overseas acquisition in its history. The company has decided to acquire Organon & Company, a leading US healthcare company, for $11.75 billion. This deal is considered the largest international acquisition in the Indian pharmaceutical sector to date.
Organon & Company is a 103-year-old New York-listed healthcare company specializing in women’s health products and medicines. Through this acquisition, Sun Pharma is strengthening its portfolio and deepening its presence in the global market.
According to the company, upon completion of this deal, Sun Pharma will join the top 25 pharmaceutical companies in the world. This is considered a major milestone for the Indian pharmaceutical industry, as it will establish an Indian company among the global pharmaceutical giants.
This acquisition is considered strategically significant for Sun Pharma. It is expected to nearly double the company’s revenue to $12.4 billion. It will also transform Sun Pharma’s business model.
Until now, Sun Pharma has been primarily known as a generic drug manufacturer. However, the acquisition of Organon will strengthen its position as a global specialty drugmaker. This will expand the company’s research, product development, and premium drug segments.
This acquisition is considered a major milestone for the company’s founder, billionaire industrialist Dilip Shanghvi. He started Sun Pharma on a small scale in 1983, and today it is one of India’s largest pharmaceutical companies.
According to experts, this deal will not only accelerate Sun Pharma’s global expansion but also serve as a strong signal to the Indian pharmaceutical sector that domestic companies are now able to make large acquisitions internationally.
However, regulatory approvals and other legal procedures are still pending for the deal to be completed. The acquisition will only become formally effective once this process is complete.
With this major move, Sun Pharma has taken a historic step toward further strengthening its position in the global pharmaceutical industry, which will have a visible impact on the company’s growth and international presence in the years to come.
